Arphra
live
S&P 5007,500.58+1.08%
NASDAQ30,406.19+2.48%
DOW51,564.7+0.14%
VIX16.78+2.32%
US10Y4.45-0.27%
EUR/USD1.1506-0.93%
GOLD4,300.5-1.26%
WTI75.22-0.90%
BTC64,442.01-1.87%
S&P 5007,500.58+1.08%
NASDAQ30,406.19+2.48%
DOW51,564.7+0.14%
VIX16.78+2.32%
US10Y4.45-0.27%
EUR/USD1.1506-0.93%
GOLD4,300.5-1.26%
WTI75.22-0.90%
BTC64,442.01-1.87%

RVTY

Revvity, Inc.
HealthcareMedical - Diagnostics & ResearchUSUSDPeers →
$99.90
+2.06%LiveJun 23, 2026
AI Brief
Market cap
$11.14B
52w range
81.22 – 118.30
P / E
EPS · FY 2025
$2.08
Volume
847.93K
Revenue · FY 2025
$2.86B
+3.67% YoY

Explain this page

Arphra AI
Business description
· company · SEC profile

Revvity, Inc.

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Founded
IPO
Jul 06, 1965
Employees
11,000
HQ
Waltham, MA
CEO
Prahlad R. Singh
CFO
Maxwell Krakowiak
Exchange
NYSE
Fiscal year
Identifiers
· company_identifiers
CIK0000031791
CUSIP714046109
ISINUS7140461093
FIGIRVTY US
LEI
Cross-listings
· companies · ISIN
  • RVTYPrimaryNew York Stock ExchangeusUSD$11.16B
  • 0KHE.LLondon Stock ExchangeusUSD$110.64M
The global universe keeps only the primary listing; the other venues for this security are shown here.